中华胃肠外科杂志最新文献

{"title":"[Translational research advances in peritoneal metastasis of gastrointestinal cancer: from molecular mechanisms to precision therapy].","authors":"H Zhang, G X Cai","doi":"10.3760/cma.j.cn441530-20260116-00042","DOIUrl":"https://doi.org/10.3760/cma.j.cn441530-20260116-00042","url":null,"abstract":"<p><p>Peritoneal metastasis is an advanced stage of gastrointestinal cancers. The Transforming growth factor-β (TGF-β), phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/Akt/mTOR), and Wnt/β-catenin signaling pathways are associated with epithelial-mesenchymal transition, mesothelial-mesenchymal transition, and the formation of an immunosuppressive microenvironment. Moreover, these changes contribute to the development of peritoneal metastasis. Besides, the immune-stromal remodeling also plays an important role in the development of this process. Recent research is increasingly focusing on targeting the PI3K/Akt/mTOR pathway and TGF-β signaling, in combination with immune checkpoint inhibitors. For treatment, cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy and pressurized intraperitoneal aerosol chemotherapy after new local therapeutic options for patients with peritoneal metastasis. This article systematically reviews the advances in basic and clinical-translational research on peritoneal metastasis in gastrointestinal cancers, which gives a reference for shifting the management of peritoneal metastasis from an empirical approach toward a more precise, intervention-based strategy.</p>","PeriodicalId":23959,"journal":{"name":"中华胃肠外科杂志","volume":"29 4","pages":"463-467"},"PeriodicalIF":0.0,"publicationDate":"2026-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147783103","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Similarities and differences between Chinese protocols and international practices in the management of peritoneal tumors].","authors":"Z X Yuan, Q F Lin, P R Zou, H Wang","doi":"10.3760/cma.j.cn441530-20260105-00009","DOIUrl":"https://doi.org/10.3760/cma.j.cn441530-20260105-00009","url":null,"abstract":"<p><p>Peritoneal surface malignancies represent a metastatic pattern of advanced gastrointestinal and other malignant tumors, which are difficult to treat and associated with poor prognosis. Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (CRS+HIPEC) is the standard treatment for peritoneal tumors recommended by the Peritoneal Surface Oncology Group International (PSOGI). In recent years, peritoneal tumors have evolved from a \"cold\" field to a \"hot\" topic in oncological academia. An increasing number of prospective clinical studies have been published worldwide, providing new insights into the management of peritoneal tumors. At the 2025 PSOGI Congress, several issues emerged as key research hotspots in peritoneal tumors, including the presentation of the CAIRO6 trial on preoperative chemotherapy for CRS, the pros and cons debate on the application value of pressurized intraperitoneal aerosol chemotherapy (PIPAC) in peritoneal tumors, the impact of pathological types on survival prognosis, the value of laparoscopic minimally invasive techniques in CRS, and the selection of chemotherapeutic agents for HIPEC. China has kept pace with international developments in the field of peritoneal tumors, conducting a series of studies ranging from clinical research to basic translational research. This article reviews the similarities and differences in the treatment of peritoneal tumors between China and abroad, as well as the pathological diagnosis and classification, patient selection for CRS, key points in the implementation of CRS and HIPEC, differences in preoperative chemotherapy regimens, and selection of HIPEC chemotherapeutic agents, aiming to provide new ideas for the therapeutic direction of peritoneal tumors.</p>","PeriodicalId":23959,"journal":{"name":"中华胃肠外科杂志","volume":"29 4","pages":"436-444"},"PeriodicalIF":0.0,"publicationDate":"2026-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147783142","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Innovative practices in the diagnosis and treatment of peritoneal surface malignancies: insights from the 15th congress of the Peritoneal Surface Oncology Group International (PSOGI)].","authors":"E Koh","doi":"10.3760/cma.j.cn441530-20260128-00063","DOIUrl":"https://doi.org/10.3760/cma.j.cn441530-20260128-00063","url":null,"abstract":"<p><p>Based on the highlights of the 15th International Congress on Peritoneal Surface Malignancies (PSOGI), this article discusses innovative practices in the diagnosis and treatment of peritoneal surface malignancies (PSM). The conference focused on optimizing cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC). Notably, the CAIRO-6 trial demonstrated that perioperative systemic therapy improves progression-free survival (PFS), while the ORCHESTRA trial provided valuable evidence for the management of synchronous peritoneal and extra-peritoneal metastases. The congress also highlighted the clinical significance of tumor biology and focused on emerging technologies such as Chimeric Antigen Receptor T-cell (CAR-T) therapy and Radspherin. Furthermore, it emphasized the importance of multidisciplinary collaboration and individualized treatment, providing significant insights for the standardization and innovative development of PSM management.</p>","PeriodicalId":23959,"journal":{"name":"中华胃肠外科杂志","volume":"29 4","pages":"450-453"},"PeriodicalIF":0.0,"publicationDate":"2026-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147782983","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Standardized W-H fundoplication procedure for gastroesophageal reflux disease (2026 version)].","authors":"","doi":"10.3760/cma.j.cn441530-20260117-00044","DOIUrl":"https://doi.org/10.3760/cma.j.cn441530-20260117-00044","url":null,"abstract":"<p><p>Based on clinical experience and expert consensus from over a hundred medical centers across China, this guideline systematically establishes a comprehensive operational framework for the standardized W-H fundoplication procedure in gastroesophageal reflux disease (GERD). To address common limitations of conventional techniques, such as postoperative dysphagia, bloating, and relatively high recurrence rates, this procedure incorporates a series of key innovations. These include precise hiatal repair with selective mesh reinforcement, restoration of the His angle, left-sided 180° fundoplication, reconstruction of the phreno-esophageal ligament, and novel three-dimensional fixation of the anti-reflux apparatus (\"Wang fixation\"). These techniques collectively enable physiological reconstruction of the anti-reflux barrier. The approach effectively balances anti-reflux efficacy with preservation of postoperative function while eliminating the need for routine division of the short gastric vessels. The guideline comprehensively covers preoperative multidisciplinary evaluation, surgical indications, perioperative management, and a standardized surgical protocol (encompassing core components such as patient positioning/port placement, esophagus/hiatal dissection, hernia repair, mesh placement, fundoplication, suture fixation, and lesser omentum reconstruction), along with structured follow-up protocols. Its core philosophy emphasizes equal importance on both anatomical repair and functional recovery, integrating individualized surgical strategies with standardized procedures. This initiative aims to advance the standardization of GERD surgical management in China, providing clinicians with systematic and practical technical guidance and decision-making support.</p>","PeriodicalId":23959,"journal":{"name":"中华胃肠外科杂志","volume":"29 4","pages":"424-435"},"PeriodicalIF":0.0,"publicationDate":"2026-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147783066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Strategies and innovative practices of European minimally invasive surgery for gastroesophageal reflux disease].","authors":"Q Wang, M M Niu, Y C Dang, R S Li, X N Liu, Luigi Bonavina","doi":"10.3760/cma.j.cn441530-20251208-00463","DOIUrl":"https://doi.org/10.3760/cma.j.cn441530-20251208-00463","url":null,"abstract":"<p><p>Gastroesophageal reflux disease (GERD) is a common esophageal disorder worldwide and can progress to erosive esophagitis, Barrett's esophagus, and even esophageal adenocarcinoma. Long-term use of proton pump inhibitors cannot fundamentally correct the functional impairment of the anti-reflux barrier, and symptom control is inadequate in approximately 40% of patients. Exploring individualized, standardized, and innovative anti-reflux surgical strategies is conducive to enhancing therapeutic efficacy and improving patient prognosis. Based on existing literature and European clinical practice experience, this article summarizes the key physiological basis of GERD, outlines classic anti-reflux surgical procedures, and reviews innovative lower esophageal sphincter (LES) augmentation techniques, including magnetic sphincter augmentation (LINX™) and the RefluxStop™ silicone implant. Regarding surgical strategy, hiatal hernia repair and LES augmentation remain core elements of anti-reflux surgery. Classic fundoplication remains reliable; however, its mechanical alteration can cause discomfort in some patients. LINX™ and RefluxStop™ offer advantages such as minimally invasive application and reversibility, effectively controlling reflux while reducing the risk of related adverse events. These novel implant technologies may progressively replace traditional fundoplication. Surgical intervention should adhere to the principle of shared decision-making to achieve individualized and precise treatment.</p>","PeriodicalId":23959,"journal":{"name":"中华胃肠外科杂志","volume":"29 4","pages":"468-477"},"PeriodicalIF":0.0,"publicationDate":"2026-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147783083","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Safety and feasibility of mobile double suspension technique in pure single-port laparoscopic D2 radical gastrectomy for distal gastric cancer].","authors":"Y Zhang, L Pu, Q M Zhao, R T Wei, G Pan, J X Wang, Y G Dai","doi":"10.3760/cma.j.cn441530-20250408-00143","DOIUrl":"https://doi.org/10.3760/cma.j.cn441530-20250408-00143","url":null,"abstract":"<p><p><b>Objective:</b> To investigate the safety and feasibility of the mobile double suspension technique in pure single-port laparoscopic D2 radical gastrectomy for distal gastric cancer. <b>Methods:</b> The mobile double suspension technique involves percutaneously inserting an 18G syringe needle loaded with a 7# silk thread on each side of the xiphoid process to act as guidewires. Guided by these wires, a suspension clip is introduced on each side of the falciform ligament. During the procedure, effective visual field exposure and organ/tissue tension are achieved by suspending and retracting the greater omentum, gastric body, left lateral lobe of the liver, and the anastomotic site. Functionally, the dual-point suspension design effectively replaces the role of one surgical assistant. <b>Results:</b> From July 2022 to July 2024, the Department of Gastrointestinal Surgery at Yunnan Cancer Hospital of Kunming Medical University successfully performed pure single-port laparoscopic D2 radical distal gastrectomy assisted by the mobile double suspension technique in 17 patients. There were no conversions to open surgery or alterations in the surgical approach. The mean operative time was (207.2±50.6) minutes, intraoperative blood loss was (91.2±86.4) ml, and the number of lymph nodes retrieved was (36±14). Postoperative pain scores on days 1, 2, and 3 were (2.4±0.6), (1.8±0.6), and (1.2±0.4), respectively. Postoperative recovery indicators showed a time to first flatus of (2.9±0.3) days, time to first liquid intake of (1.5±0.7) days, drainage tube placement duration of (5.1±0.3) days, and postoperative hospital stay of (7.5±2.7) days. Two patients developed Clavien-Dindo grade III complications: one case of duodenal stump leakage and one case of anastomotic bleeding. Both complications were successfully managed with conservative treatment measures. <b>Conclusions:</b> The application of the mobile double suspension technique in pure single-port laparoscopic D2 radical distal gastrectomy can reduce the technical difficulty and shorten the operative time for single-port laparoscopic gastric cancer surgery, demonstrating its safety and feasibility.</p>","PeriodicalId":23959,"journal":{"name":"中华胃肠外科杂志","volume":"29 4","pages":"528-532"},"PeriodicalIF":0.0,"publicationDate":"2026-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147783108","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Preliminary analysis of mFOLFOXIRI plus bevacizumab combined with cytoreductive surgery for resectable peritoneal metastases from colorectal cancer: a prospective,randomized phase II clinical trial].","authors":"H M Liu, H B Hu, Y Y Kuang, Z T Lin, K L Yang, H Wang","doi":"10.3760/cma.j.cn441530-20260110-00026","DOIUrl":"https://doi.org/10.3760/cma.j.cn441530-20260110-00026","url":null,"abstract":"&lt;p&gt;&lt;p&gt;&lt;b&gt;Objective:&lt;/b&gt; To investigate the efficacy and safety of mFOLFOXIRI combined with bevacizumab plus cytoreductive surgery (CRS) in patients with resectable peritoneal metastasis of colorectal cancer (CRC). &lt;b&gt;Methods:&lt;/b&gt; A single-center, prospective randomized controlled design was conducted. Inclusion criteria: confirmed synchronous or metachronous peritoneal metastasis of CRC, aged &gt;18 years, adequate organ function and tolerance to chemotherapy, resectable peritoneal lesions with peritoneal cancer index (PCI) &lt;20, Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1, and tolerance to CRS. Exclusion criteria: intolerance or inefficacy to oxaliplatin, distant unresectable metastasis, emergency surgery, active malignancy, history of thromboembolism, pregnancy or lactation, and other severe comorbidities. Between August 2022 and December 2024, eligible patients with resectable peritoneal metastasis of CRC treated at the Sixth Affiliated Hospital, Sun Yat-sen University were enrolled and randomly assigned at a 1:1 ratio to the neoadjuvant therapy group (mFOLFOXIRI plus bevacizumab followed by CRS) or the direct CRS group. The primary endpoint was the 1-year progression-free survival rate. Secondary endpoints included the response to neoadjuvant therapy, completeness of cytoreduction (CC) score, length of postoperative hospital stay, and postoperative complications. &lt;b&gt;Results:&lt;/b&gt; A total of 53 patients who underwent surgery were included, with 19 in the neoadjuvant therapy group and 34 in the direct CRS group. There were no statistically significant differences between the two groups in age, sex, BMI, primary tumor location, pathological type, pattern of peritoneal metastasis (synchronous/metachronous), extraperitoneal metastasis, history of prior systemic therapy, baseline radiological PCI score, or tumor markers (CEA, CA19-9, CA125) (all &lt;i&gt;P&lt;/i&gt;&gt;0.05). In the neoadjuvant therapy group, post-treatment radiological PCI score was significantly lower than baseline [&lt;i&gt;M&lt;/i&gt;(&lt;i&gt;Q&lt;/i&gt;&lt;sub&gt;1&lt;/sub&gt;,&lt;i&gt;Q&lt;/i&gt;&lt;sub&gt;3&lt;/sub&gt;): 6.0 (4.0, 12.0) vs. 8.0 (5.0, 12.0), &lt;i&gt;Z&lt;/i&gt;=-3.086, &lt;i&gt;P&lt;/i&gt;=0.002], and CEA was significantly reduced [3.9 (2.8, 7.3) μg/L vs. 7.7 (4.1, 16.1) μg/L, &lt;i&gt;Z&lt;/i&gt;=-2.809, &lt;i&gt;P&lt;/i&gt;=0.005]. Hemoglobin and albumin levels were also decreased [107.0 (97.5, 117.0) g/L vs. 134.0 (118.0, 140.5) g/L, &lt;i&gt;Z&lt;/i&gt;=-3.019, &lt;i&gt;P&lt;/i&gt;=0.003;35.9 (34.9, 39.3) g/L vs. 40.0 (37.3, 42.9) g/L, &lt;i&gt;Z&lt;/i&gt;=-2.213, &lt;i&gt;P&lt;/i&gt;=0.027], with all differences statistically significant (all &lt;i&gt;P&lt;/i&gt;&lt;0.05). CA19-9 and CA125 showed a downward trend, but the differences were not statistically significant (all &lt;i&gt;P&lt;/i&gt;&gt;0.05). There were no significant between-group differences in CC grade (proportion of CC 0-1: 17/19 vs. 88.2% [30/34]), length of postoperative hospital stay [10.0 (7.0, 13.0) days vs. 13.0 (9.3, 14.0) days], or incidence of severe postoperative complications (8/19 vs. 38.2%[13/34]) (all &lt;i&gt;P&lt;/i&gt;&gt;0.05). The proportion of 1-year prog","PeriodicalId":23959,"journal":{"name":"中华胃肠外科杂志","volume":"29 4","pages":"484-491"},"PeriodicalIF":0.0,"publicationDate":"2026-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147783046","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Safety and efficacy of minimally invasive surgery for primary gastric gastrointestinal stromal tumors].","authors":"L C Hou, L X Yang, M Wang, H Cao","doi":"10.3760/cma.j.cn441530-20251129-00455","DOIUrl":"https://doi.org/10.3760/cma.j.cn441530-20251129-00455","url":null,"abstract":"&lt;p&gt;&lt;p&gt;&lt;b&gt;Objective:&lt;/b&gt; To investigate the surgical safety and oncological efficacy of minimally invasive surgery (MIS) for primary gastric gastrointestinal stromal tumors (GISTs) with a maximum diameter of ≤5 cm. &lt;b&gt;Methods:&lt;/b&gt; A retrospective cohort study was conducted. The inclusion criteria were as follows: patients undergoing radical local resection via MIS, pathologically confirmed primary gastric GISTs, maximum tumor diameter ≤5 cm, and complete available clinicopathological data, adjuvant therapy information and follow-up records. The exclusion criteria included multiple GISTs, a history of other malignant tumors, and distant metastasis or local invasion detected preoperatively or intraoperatively. Clinical data of 517 patients with gastric GISTs who underwent radical surgery at Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine from July 2018 to December 2024 were retrospectively collected. All patients were divided into four groups according to surgical approaches: laparoscopic surgery group (Lap group, n=411), robotic surgery group (Robot group, n=9), endoscopic surgery group (Endo group, n=44), and laparoscopic-endoscopic cooperative surgery group (LECS group, n=53). Partial gastrectomy was performed in the Lap, Robot and LECS groups, while endoscopic submucosal dissection was the only surgical method in the Endo group. The Lap group was further subdivided into the favorable anatomical location subgroup (Lap-F group, e.g., anterior wall, greater curvature) and the unfavorable anatomical location subgroup (Lap-C group, e.g., posterior wall, lesser curvature, cardia, pylorus) based on tumor location. The LECS group was divided into the laparoscopy-dominated resection subgroup (LECS-L group) and the endoscopy-dominated resection subgroup (LECS-E group) according to the resection modality. Perioperative outcomes and follow-up data of patients in different groups were observed and analyzed. &lt;b&gt;Results:&lt;/b&gt; Among all the patients, 227(43.9%) were male , with a median age of 62.5 (55.0, 68.0) years. There were 105 cases with tumor diameter ≤2.0 cm and 412 cases with 2.1-5.0 cm. According to postoperative pathological risk stratification, 98 cases were very low-risk, 368 low-risk, 36 moderate-risk and 15 high-risk. Baseline data comparison showed no statistically significant differences in gender, age and mitotic count among the Lap, Robot, Endo and LECS groups (all &lt;i&gt;P&lt;/i&gt;&gt;0.05), while significant differences were found in tumor growth direction, tumor diameter and pathological risk grade (all &lt;i&gt;P&lt;/i&gt;&lt;0.001). No statistically significant baseline differences were observed between the Lap-F and Lap-C groups, nor between the LECS-L and LECS-E groups (all &lt;i&gt;P&lt;/i&gt;&gt;0.05). All surgeries were successfully completed in the four groups. R0 resection was achieved in all patients of the Lap, Robot and LECS groups, while the surgical margin could not be evaluated in the Endo group. The average operation time of the four gr","PeriodicalId":23959,"journal":{"name":"中华胃肠外科杂志","volume":"29 4","pages":"510-517"},"PeriodicalIF":0.0,"publicationDate":"2026-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147783053","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Optimization strategies for comprehensive perioperative management in metabolic and bariatric surgery].","authors":"R Wei, Z P Wu, L N Wu, X M Peng, J G Yang","doi":"10.3760/cma.j.cn441530-20260106-00018","DOIUrl":"10.3760/cma.j.cn441530-20260106-00018","url":null,"abstract":"<p><p>Perioperative holistic management in bariatric and metabolic surgery has evolved from conceptual consensus to an era of refined clinical practice and innovative care models. Anchored in a patient-centered philosophy, this paradigm integrates systematic evaluation, standardized clinical pathways, and personalized interventions to establish a seamless continuum of care spanning the preoperative, intraoperative, and postoperative phases. Future advancements must be underpinned by robust clinical guidelines and evidence-based medicine, prioritizing the continuous optimization of management protocols and long-term follow-up systems to ultimately ensure sustained patient health benefits.</p>","PeriodicalId":23959,"journal":{"name":"中华胃肠外科杂志","volume":"29 3","pages":"322-326"},"PeriodicalIF":0.0,"publicationDate":"2026-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147487620","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Expert consensus on the responsibilities of robot-assisted gastric cancer surgery assistants (2026 version)].","authors":"","doi":"10.3760/cma.j.cn441530-20260111-00028","DOIUrl":"10.3760/cma.j.cn441530-20260111-00028","url":null,"abstract":"<p><p>As a complex surgical method, the success of robot-assisted radical gastrectomy for gastric cancer depends not only on the superb skills of the operating surgeon, but also on the close cooperation of the assistant team. However, there is still a lack of unified standards for the training, assessment and responsibility definition of assistants in robot-assisted gastric cancer surgery at home and abroad. To standardize the operation procedures of such surgical assistants, clarify their specific roles and tasks during the perioperative period, and further improve the overall efficiency of the surgical team and the safety guarantee of patients, the Clinical Research Cooperative Group for Robotic Surgery of the Gastric Cancer Committee of the Chinese Anti-Cancer Association specially invited domestic experts in the field of gastrointestinal surgery. Focusing on 16 most common clinical questions, relying on existing evidence-based medical evidence and rich clinical practice experience, 16 recommendations were formulated, and the <i>Expert Consensus on the Responsibilities of Assistants in Robot-Assisted Gastric Cancer Surgery (2026 Edition)</i> was discussed and established. This consensus systematically clarifies for the first time the scope of responsibilities and operational specifications of assistants in robot-assisted gastric cancer surgery throughout the perioperative period, aiming to construct a systematic and standardized framework for the operational responsibilities of such assistants, and promote the standardized and homogeneous development of robot-assisted gastric cancer surgery in China.</p>","PeriodicalId":23959,"journal":{"name":"中华胃肠外科杂志","volume":"29 2","pages":"141-154"},"PeriodicalIF":0.0,"publicationDate":"2026-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146195738","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}